Gallery: Stunning mansion on Lake Minnetonka hits market for $10M
Set on the grounds of what was once the Van Dusen family's summer cottage and now called The Forever Estate, the 8,297-sq.ft. home is set in the private Baycliffe gated community.
Listing agent Andrew Wolf, with Edina Realty, says the 2015 home "blends French provincial charm with countryside cottage allure," with elements of the original Van Dusen incorporated into the current mansion.
This includes a 16th Century Venetian wellhead that featured on the original Van Dusen property, and a Tiffany garden gate that marked the entrance to the original cottage estate. The lower level brick wall was also created using old pavers that spanned the original estate property.
View the 15 images of this gallery on the original article
The home at 4750 Baycliffe Drive is set on a 1.22-acre plot that includes 210-feet of shoreline on the southwest corner of Lake Minnetonka, just west of Smithtown Bay. An expansive patio overlooking the lake is also home to a heated outdoor pool, hot tub, and pool house.
"A stunning owner's suite on the upper level showcases a private balcony with panoramic lake views, a dramatic tufted velvet wall, gas fireplace, and a luxurious ensuite with double steam showers, jetted tub, and a coffee bar," the listing reads.
The Wolfs say that one of the "truly exceptional facets of the home" is the 3,000-sq.ft.-plus of garage space, which includes two upper levels and one lower level area with a private entrance and space for 6+ cars.
The Wolf Group at Edina Realty has the listing at 4750 Baycliffe Drive, Excelsior.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
OSE Immunotherapeutics Appoints Thomas Gidoin as Chief Financial Officer
NANTES, France, August 20, 2025 – 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced the appointment of Thomas Gidoin as Chief Financial Officer. Thomas joins the Executive Committee, bringing over 15 years of deep international expertise in capital markets, financial strategy, and governance to the company. Thomas Gidoin is an experienced biopharma finance executive with a strong track record in strategic financial leadership, both in private and public companies. Prior to joining OSE Immunotherapeutics, he served as Chief Financial Officer at Advesya, a privately held Franco-Swiss clinical-stage biotech company in oncology and autoimmune diseases, after having spent 8 years as CFO of GenSight Biologics, a Euronext-listed French biopharma company developing gene therapies for neurodegenerative retinal diseases, where he led the company's financing strategy from the Series B to the IPO on Euronext Paris and a number of follow-on transactions and structured financings. Previously, Thomas was Vice President of Finance at DBV Technologies, where he led the Corporate Finance team and contributed to public offerings and private placements, including the dual listing of the company on the US NASDAQ. Prior to this, Thomas served as Northern Europe Business Controller at PregLem in London, held several positions at Ipsen, including UK Operations Controller in London and Senior Financial Analyst in the Global Operations division in Paris. He started his career in audit at Ernst & Young in Paris. He holds master's degrees in international finance from ESGF Paris and in international management from NEOMA Business School. Thomas succeeds Anne-Laure Autret-Cornet, marking a new phase in the company's financial leadership. Nicolas Poirier, Chief Executive Officer, OSE Immunotherapeutics, commented: 'Thomas joins OSE Immunotherapeutics with deep experience in biotech capital markets financing and strategic financial planning. He has a clear understanding of what it takes to support innovation through disciplined execution and rigorous cash management. His arrival comes at a time when financial leadership is key to advancing our two late-stage assets and continuing to leverage our research platform. His expertise will further reinforce the management team to prepare the next phase of growth with clarity and focus.' Thomas Gidoin, Chief Financial Officer, OSE Immunotherapeutics, said: 'I am thrilled to join OSE Immunotherapeutics at such a pivotal moment in its journey. With two late-stage assets in oncology and inflammation, boosted by a highly innovative research platform, the company is well positioned to create meaningful long-term value through clear multiple short-term inflexion points. I look forward to working closely with the leadership team to help unlock the full potential of OSE's innovative pipeline.' ABOUT OSE IMMUNOTHERAPEUTICS OSE Immunotherapeutics is a biotech company dedicated to developing first-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&I) that address the unmet patient needs of today and tomorrow. We partner with leading academic institutions and biopharmaceutical companies in our efforts to develop and bring to the market transformative medicines for people with serious diseases. OSE Immunotherapeutics is based between Nantes and Paris and is quoted on Euronext. Additional information about OSE Immunotherapeutics assets is available on the Company's website: Follow us on LinkedInContacts Fiona Dé Contact Media France: FP2COMFlorence Portejoiefportejoie@ 6 07 768 283 Contact Media US:RooneyPartners LLCKate Barrettekbarrette@ 212 223 0561 Forward-looking statementsThis press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics' management considering its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate. These forward-looking statements include statements typically using conditional and containing verbs such as 'expect', 'anticipate', 'believe', 'target', 'plan', or 'estimate', their declensions and conjugations and words of similar import. Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics' shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance. This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF on April 30, 2025, including the annual financial report for the fiscal year 2024, available on the OSE Immunotherapeutics' website. Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements. Attachments EN_2508_20_CFO_vf EN_2508_20_CFO_vf
Time Business News
7 hours ago
- Time Business News
Exploring Regulations Related to GBL Kaufen Across Europe
When it comes to chemical substances used across industries, one compound that often makes headlines is gamma-butyrolactone, more commonly known as GBL. Its versatility as a solvent and cleaner is widely recognized, yet the compound also carries strict legal scrutiny because of its potential misuse. For anyone curious about the rules surrounding gbl Kaufen (buying GBL) in Europe, understanding the patchwork of regulations can feel overwhelming. Different countries take different stances, and navigating these legal frameworks requires awareness and care. This blog takes a closer look at how GBL is regulated across Europe, what buyers should know, and why staying informed matters. GBL is a chemical solvent found in industrial cleaners, paint removers, and certain degreasers. In legitimate contexts, it plays an important role in manufacturing and cleaning industries. However, because GBL can convert into gamma-hydroxybutyrate (GHB) in the body, authorities view it as a substance with high potential for misuse. That dual-use nature both industrially valuable and potentially harmful—makes regulation complicated. Many European countries have implemented specific restrictions to control how gbl Kaufen takes place, ensuring buyers are legitimate businesses or individuals with valid purposes. The European Union doesn't have a single law that applies uniformly to all member states for GBL. Instead, it issues guidelines that countries can interpret and enforce individually. At the EU level, GBL is listed as a 'drug precursor,' meaning it can be controlled and monitored due to its potential use in producing banned substances. This classification does not automatically make gbl Kaufen illegal, but it does require that sales and purchases be tracked, with authorities paying close attention to unusual or suspicious activities. In Germany, GBL is tightly controlled. The government considers its potential misuse serious enough to impose stringent restrictions on how it can be sold and purchased. To legally buy GBL in Germany, companies usually need licenses and must demonstrate a clear industrial purpose for the chemical. Private buyers face significant barriers, and unauthorized purchases could lead to legal consequences. For Germans, gbl Kaufen is not as straightforward as clicking 'add to cart.' Instead, it requires proof of legitimacy, registration with authorities, and often, compliance checks. France also classifies GBL as a regulated substance. French authorities treat it as a chemical under strict monitoring, and buyers must prove industrial or laboratory usage. Over the years, France has taken strong action against unauthorized sales, including online vendors who attempt to bypass controls. This makes gbl Kaufen within France a heavily monitored process. While the UK is no longer part of the European Union, its stance on GBL is worth noting, especially for businesses trading across borders. In the UK, GBL is classified as a Class C controlled substance under the Misuse of Drugs Act when intended for human consumption. This means industrial and commercial uses are still permitted, but sellers and buyers must keep detailed records. Anyone attempting gbl Kaufen for personal use faces serious legal risks. The Netherlands has built its reputation on pragmatic drug policies, but when it comes to GBL, the rules are clear. Dutch authorities regulate sales to prevent misuse while still allowing industrial businesses to access the chemical. Vendors are required to verify the legitimacy of buyers. If someone attempts gbl Kaufen without proper documentation, the transaction will not proceed. This balanced approach aims to safeguard public health without unnecessarily harming legitimate industry operations. Across Europe, policies vary significantly: Spain : Authorities keep a close eye on GBL but generally allow industrial purchases with proper documentation. : Authorities keep a close eye on GBL but generally allow industrial purchases with proper documentation. Italy : Regulations exist but enforcement focuses on preventing diversion into unauthorized uses. : Regulations exist but enforcement focuses on preventing diversion into unauthorized uses. Nordic countries: Typically adopt very strict approaches, aligning closely with Germany's rules. In every case, gbl Kaufen requires navigating country-specific laws. Even if the EU provides general guidelines, enforcement rests on national governments. One of the biggest challenges regulators face is online sales. With e-commerce, buyers and sellers can connect across borders easily. However, customs authorities in Europe actively monitor shipments suspected of containing controlled chemicals. For instance, if someone tries to order GBL from a less-regulated country into Germany or France, the package could be seized, and legal consequences could follow. This means that online gbl Kaufen is not only risky but often legally problematic, especially without the proper licenses. At first glance, it may seem confusing why one country allows easier access to GBL while another imposes near-total restrictions. The reason lies in how each government assesses risk. Countries with a history of substance misuse tend to implement stricter laws. Nations with strong industrial reliance on GBL may focus on monitoring rather than outright bans. Legal traditions also shape enforcement some prefer heavy penalties, while others emphasize oversight and reporting. This patchwork creates a complex landscape for anyone interested in gbl Kaufen across Europe. Attempting to bypass regulations carries significant risks. Beyond the possibility of confiscated shipments, individuals or businesses could face: Heavy fines Criminal charges Blacklisting from suppliers Reputational damage Because of these risks, both companies and individuals should carefully research the legal status of gbl Kaufen in their specific country before making any purchase. If your industry requires GBL, here are some practical tips to stay compliant: Verify your supplier : Always check whether they are authorized to sell GBL. : Always check whether they are authorized to sell GBL. Keep documentation : Maintain purchase records, licenses, and proof of legitimate use. : Maintain purchase records, licenses, and proof of legitimate use. Stay updated : Laws can change, so follow national and EU-level updates. : Laws can change, so follow national and EU-level updates. Consult legal experts: Especially if your business operates across borders. Following these steps ensures that gbl Kaufen remains a safe and lawful process. Looking ahead, it's possible that the European Union will push for more harmonized regulations on substances like GBL. This could mean stricter monitoring across all member states or the development of a unified licensing system. For now, the fragmented system continues, and buyers must remain vigilant. Anyone involved in gbl Kaufen should prepare for potential regulatory tightening in the future. The story of GBL in Europe is one of balance: balancing legitimate industrial needs against the risks of misuse. Regulations vary from country to country, making it essential to understand local laws before making any purchase. Whether you're a business needing solvents for cleaning or manufacturing, or an individual researching chemical regulations, the key takeaway is clear: gbl Kaufen is not a one-size-fits-all process across Europe. Laws differ, enforcement varies, and compliance is critical. By staying informed and cautious, buyers can ensure they remain on the right side of the law while still accessing the chemical for legitimate purposes. TIME BUSINESS NEWS
Bloomberg
8 hours ago
- Bloomberg
Hackers Accessed 850,000 Orange Belgium Customer Accounts
Orange SA 's Belgian business said that hackers gained access to data from 850,000 customer accounts, in the third major cyberattack targeting the French telecommunications firm this year. The company detected that one of its IT systems had been compromised at the end of July, exposing data including customer names, phone numbers, SIM card and tariff details, according to a statement on Wednesday. No email addresses, passwords or bank details were accessed, it added.
